Get a Sample
Schedule a Meeting
Get a Sample
Table Of Content
June 2025
The global glucose tolerance test market size is calculated at USD 56.76 billion in 2025 and is forecasted to reach around USD 134.83 billion by 2034, accelerating at a CAGR of 10.09% from 2025 to 2034. The North America market size surpassed USD 19.13 billion in 2024 and is expanding at a CAGR of 10.24% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
The global glucose tolerance test market size accounted for USD 51.56 billion in 2024 and is predicted to increase from USD 56.76 billion in 2025 to approximately USD 134.83 billion by 2034, expanding at a CAGR of 10.09% from 2025 to 2034. The market is experiencing significant growth due to the rising prevalence of diabetes and prediabetes. The growing awareness of health and routine screening practices further supports market growth. Additionally, technological advancements in diagnostic devices are expected to contribute to market expansion in the coming years.
Artificial intelligence (AI) is transforming the glucose tolerance test market by enhancing diagnosis, treatment, and management of diabetes. AI-driven tools can analyze data from Continuous Glucose Monitors (CGMs) and other sources to predict glucose levels, personalize treatment strategies, and support patient self-management. AI can also analyze GTT data to classify diabetes types more accurately, potentially assisting primary healthcare providers who lack access to specialized tests. Moreover, AI can forecast glucose fluctuations and tailor treatment plans, including insulin dosage recommendations. Tools powered by AI, such as smartphone apps and wearable devices, give real-time feedback, analysis, and advice to patients, empowering them to manage their condition more effectively.
The U.S. glucose tolerance test market size was exhibited at USD 13.39 billion in 2024 and is projected to be worth around USD 35.74 billion by 2034, growing at a CAGR of 10.32% from 2025 to 2034.
What Made North America the Dominant Region in the Glucose Tolerance Test Market in 2024?
North America dominated the market while holding the largest share in 2024. This is mainly due to its large and growing diabetic population, robust healthcare infrastructure, high adoption of advanced technologies, and favorable regulatory environment. There is a strong emphasis on combating diabetes and improving patient care, which supports the market growth. The presence of major players like Abbott Laboratories, Roche Diagnostics, Dexcom Inc., Medtronic plc, and Ascensia Diabetes Care Holdings AG has contributed to the region's dominance. North America is a leader in adopting new healthcare technologies, including advanced glucose monitoring devices that complement GTT. The U.S. regulatory environment encourages innovation and the commercialization of healthcare products, including diagnostic tools.
U.S. Glucose Tolerance Test Market Trends
The U.S. held the maximum share of the market in 2024, mainly driven by its high rates of diabetes and prediabetes, which create strong demand for advanced glucose monitoring and diagnostic tools. This leadership is supported by the country's sophisticated healthcare infrastructure, quick adoption of innovative point-of-care technologies, and a comprehensive reimbursement system covering these tests. Additionally, the presence of major international manufacturers, along with public awareness campaigns and prevention initiatives, significantly contributes to the country’s leadership in the market.
In June 2024, Abbott introduced Libre Rio, its first over-the-counter continuous glucose monitoring (CGM) system in the U.S., designed for adults with Type 2 diabetes who do not use insulin. This system is aimed at individuals managing their diabetes through lifestyle changes like diet and exercise. The technology powering this device is now available for U.S. consumers with and without diabetes through two FDA-cleared over-the-counter CGM systems.
(Source: https://www.abbott.com)
What Makes Asia Pacific the Fastest-Growing Region in the Glucose Tolerance Test Market?
Asia Pacific is expected to experience the fastest growth in the market during the projection period. This growth is mainly driven by the high prevalence of diabetes, increasing awareness about the early detection and prevention, and government initiatives promoting early diagnosis and management. Further growth is fueled by technological advancements, especially in non-invasive testing methods, and a shift toward preventive healthcare. The development of non-invasive glucose testing technologies, smart monitoring systems, and wearable devices is expanding market options by offering convenient and user-friendly solutions. Governments of several Asian countries are working to improve healthcare infrastructure, promote digital health monitoring, and support the development of innovative glucose monitoring technologies, which drive market growth.
India Glucose Tolerance Test Market Trends
India plays a major role in the market. This is mainly because of the country's alarming rise in diabetes and prediabetes prevalence. This surge has led to increased awareness about the importance of early diagnosis and management, consequently boosting the demand for GTTs. The Indian government is actively addressing this through initiatives like the National Programme for Prevention and Control of Non-Communicable Diseases (NP-NCD), which focuses on screening, early diagnosis, and promoting healthy lifestyles, ultimately contributing to improved diabetes care in India.
Why is Europe Considered a Notable Region in the Glucose Tolerance Test Market?
Europe is expected to experience notable growth in the market. This is due to the increasing prevalence of diabetes, advancements in technology, and higher healthcare spending. Europe is at the forefront of adopting new technologies in diabetes management, including continuous glucose monitoring (CGM) systems and Bluetooth-enabled meters. Rising healthcare expenditure, coupled with a focus on early diagnosis and preventative care, drives the growth of the GTT market. The region holds a significant market share, second only to the Americas, and is witnessing increased adoption of advanced medical devices and technologies.
What Opportunities Exist in the Glucose Tolerance Test Market in Latin America?
Latin America plays a distinctive role in the market. This is primarily due to the increasing prevalence of diabetes, especially type 2, and greater awareness of the importance of early detection and management. Growing awareness about the risks associated with diabetes and the benefits of early diagnosis prompts more individuals to undergo glucose tolerance tests. This growth is further supported by government initiatives focused on diabetes prevention and treatment, as well as advancements in diagnostic technologies and collaborations within the healthcare sector.
What Factors Contribute to the Middle East & Africa Glucose Tolerance Test Market?
The market in the Middle East & Africa is expected to grow at a steady rate in the upcoming period, driven by rising diabetes prevalence, increased awareness, and government initiatives promoting early detection and management of the disease. Public health campaigns, partnerships with diabetes foundations, and government focus on chronic disease management are raising awareness about diabetes and the necessity of early diagnosis and monitoring, including GTTs. This growth is further fueled by technological advancements, particularly in non-invasive and continuous glucose monitoring solutions, and strategic partnerships focused on diabetes care.
The glucose tolerance test market encompasses products, services, and technologies used to perform glucose tolerance testing, a diagnostic procedure employed to assess how efficiently the body metabolizes glucose. Primarily used in the diagnosis of diabetes, gestational diabetes, and insulin resistance, the GTT evaluates blood glucose levels after fasting and following the ingestion of glucose over a specific time period. The market includes test kits, analyzers, reagents, and lab services, catering to various end users such as hospitals, diagnostic labs, and home care settings.
Glucose tolerance tests are crucial for diagnosing and managing diabetes and other conditions that affect glucose metabolism. This market is growing due to the rising prevalence of diabetes and other metabolic disorders, which require accurate diagnostic tools. The glucose tolerance test (GTT) assesses how effectively the body processes glucose, helping to diagnose conditions such as diabetes mellitus and gestational diabetes. The increase in diabetes cases, driven by lifestyle changes, along with advancements in testing methods and equipment, fuels the growth of this market.
| Report Coverage | Details |
| Market Size by 2034 | USD 134.83 Billion |
| Market Size in 2025 | USD 56.76 Billion |
| Market Size in 2024 | USD 51.56 Billion |
| Market Growth Rate from 2025 to 2034 | CAGR of 10.09% |
| Dominating Region | North America |
| Fastest Growing Region | Asia Pacific |
| Base Year | 2024 |
| Forecast Period | 2025 to 2034 |
| Segments Covered | Product Type, Mode of Testing, End User, Application, and Region |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Growing Global Prevalence of Diabetes
The main driver of the glucose tolerance test market is the growing global prevalence of diabetes. The diabetes burden is further driven by lifestyle changes and an aging population. Worldwide, healthcare systems are expanding screening programs and incorporating GTTs into routine diagnostic programs. The rising awareness of gestational diabetes further drives the market growth. Screening for gestational diabetes during pregnancy is now standard practice, boosting the demand for GTTs. As a result, there is a higher demand for diagnostic tools like GTTs for early detection and management of diabetes. Additionally, increased government funding for diabetes research and diagnostics has contributed to market growth.
Limited Access to Healthcare Services
The primary obstacle in this market is limited access to healthcare services, especially in underdeveloped and rural areas. The high cost of advanced testing devices also presents a barrier, particularly in low- and middle-income countries where affordable diagnostics are crucial. Overall, insufficiently trained personnel, poor infrastructure, and low awareness about diabetes screening in certain regions restrict the availability and use of GTTs. These issues hinder the widespread adoption of GTTs for diabetes diagnosis and management, impacting market growth.
Integration of Digital Health Solutions and the Development of Non-Invasive Monitoring Methods
A key future opportunity in the glucose tolerance test market lies in the integration of digital health solutions and the development of non-invasive monitoring methods. This includes using mobile apps, cloud-based platforms, and other digital tools to track, store, and analyze glucose readings from GTTs, enabling personalized diabetes management and early intervention. These tools enable patients to easily monitor their glucose levels, share data with healthcare providers, and receive personalized feedback and recommendations. Digital health solutions can also customize GTT protocols and treatment plans to meet individual patient needs based on their unique data and responses, thereby reducing errors and enhancing patient confidence in the results.
What Made Oral Glucose Tolerance Test (OGTT) Kits the Dominant Segment in the Glucose Tolerance Test Market in 2024?
The oral glucose tolerance test (OGTT) kits segment dominated the market with the largest share in 2024. This is mainly due to their diagnostic accuracy and ability to detect different stages of glucose intolerance, including gestational diabetes. OGTT kits provide a more comprehensive assessment of glucose metabolism than simpler tests like fasting blood glucose tests, making them essential for identifying those at risk of developing type 2 diabetes or with gestational diabetes. By identifying individuals with impaired glucose tolerance early, OGTT kits facilitate intervention strategies such as lifestyle changes and medication to prevent or delay progression to type 2 diabetes.
The reagents & consumables segment is expected to experience the fastest growth in the upcoming period, as they are essential in performing the necessary analysis. The growth of the segment is also driven by the increasing prevalence of diabetes, innovations in testing procedures, and the need for frequent testing. Growing awareness about early diagnosis and management of diabetes, along with public health campaigns, is increasing demand for GTTs and related products. Moreover, the need for regular glucose monitoring, especially among individuals with diabetes or prediabetes, drives the use of reagents and consumables. The development of more accurate and accessible glucose monitoring solutions further supports segmental growth.
How Does the Laboratory-Based Testing Segment Dominate the Glucose Tolerance Test Market in 2024?
The laboratory-based testing segment held the largest market share in 2024. This is mainly because of its higher accuracy and reliability compared to point-of-care testing, as well as its ability to perform a broader range of tests and provide detailed analysis. Laboratory tests, especially those using enzymatic methods like glucose oxidase (GOx), offer high precision in measuring glucose levels. These enzymatic reactions are well-understood, and their results are less affected by other substances. Labs can also analyze additional biochemical markers, such as lipids and electrolytes, which are important for evaluating overall metabolic health and identifying potential diabetes-related complications.
The point-of-care testing segment is likely to grow at the fastest rate during the forecast period due to its convenience, rapid results, and increasing focus on a patient-centric care approach. Point-of-care testing devices deliver quick results, allowing timely adjustments to diet, exercise, or medication. The rapid shift toward home care setting further supports segmental growth. POCT enables individuals to monitor their glucose levels conveniently without visiting a clinic or hospital. Rising awareness about diabetes management and the availability of user-friendly devices are boosting adoption. There is a growing trend toward decentralized healthcare and patient empowerment, with individuals actively participating in their health management.
Why Did the Gestational Diabetes Screening Segment Dominate the Glucose Tolerance Test Market in 2024?
The gestational diabetes screening segment maintained dominance in the market in 2024. The dominance of the segment stems from the increased incidence of gestational diabetes mellitus (GDM) and the need for early detection and treatment to prevent adverse pregnancy outcomes. GDM can cause complications like macrosomia, neonatal hypoglycemia, and a higher likelihood of cesarean delivery, underscoring the importance of early diagnosis and treatment. Advances in diagnostic methods, such as the 1-step 75-g 2-hour OGTT, and strategies like using HbA1c as a screening tool, further support this dominance.
The insulin resistance diagnosis segment is expected to grow at the highest CAGR in the coming years. This is primarily due to the rising prevalence of diabetes and prediabetes, along with advancements in diagnostic tools and a better understanding of the condition. Insulin resistance, a key factor in developing type 2 diabetes, is now recognized as a significant health concern, which has increased the demand for accurate and accessible diagnostic methods. This has led to a stronger focus on addressing it as part of overall metabolic health management. Improvements in glucose monitoring devices, minimally invasive testing techniques, and the integration of real-time data monitoring are boosting the accuracy and accessibility of insulin resistance diagnosis.
How Does the Hospitals Segment Lead the Glucose Tolerance Test Market in 2024?
The hospitals segment led the market in 2024. This is because of the high volume of tests conducted for diabetes diagnosis and management in hospitals, combined with the global rise in diabetes cases. Hospitals are the main setting for diagnosing, treating, and caring for diabetes, which creates a high demand for GTTs. They are where most people with diabetes get their initial diagnosis, ongoing care, and treatment plans, making them a central hub for GTTs. Hospitals handle many patients needing screening, diagnosis, and management of diabetes, which directly increases the demand for GTTs. They are equipped with the latest technology and skilled professionals to perform GTTs accurately and efficiently.
The homecare settings segment is expected to grow at the fastest CAGR over the projection period. The growth of the segment is driven by patients' increasing preference for testing at home, the rising prevalence of diabetes and prediabetes, and advancements in point-of-care technology. The rapid shift toward a homecare approach boosts the demand for POCT for managing chronic conditions like diabetes. More patients prefer managing their health from home, which leads to higher adoption of home-based glucose monitoring devices. The integration of glucose monitoring with remote patient monitoring systems enables continuous tracking and timely intervention by healthcare providers, offering a more cost-effective alternative to frequent clinic visits for glucose testing.
By Product Type
By Mode of Testing
By Application
By End User
By Region
For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
June 2025
June 2025
July 2024
October 2024